Milind Bhatt

Milind Bhatt investigates IDH1-mutated intrahepatic cholangiocarcinoma and the clinical development of IDH1 inhibitors. His research contributed to the understanding of how IDH1 gain-of-function mutations produce the oncometabolite 2-hydroxyglutarate that drives epigenetic reprogramming and cholangiocarcinoma pathogenesis. He contributed to clinical evaluation of ivosidenib in IDH1-mutated cholangiocarcinoma, including the ClarIDHy trial demonstrating improved progression-free survival that led to FDA approval of ivosidenib in this setting. His translational work advances understanding of IDH inhibitor mechanisms of action and resistance in cholangiocarcinoma.